While multiple cancer therapies are associated with cardiac dysfunction, this review concerns mostly therapies with the most robust evidence for CTRCD, including anthracyclines, HER2-targeted therapies like trastuzumab, and anti-VEGF agents. The gene discussed is VEGFA; the disease is cancer.